Clinical trials: Respiratory Tract Infection
Pharyngitis
Efficacy and Safety of Meloxicam vs. Naproxen Sodium in Patients With Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis
Study to assess the efficacy and tolerability of Meloxicam once daily dose of 7.5 mg and 15 mg compared with 1100 mg of naproxen sodium in the symptomatic treatment of acute non bacterial pharyngitis or pharyngo-tonsillitis, over…
- Trial name
- NCT02183038
- Testing
- Meloxicam low, Meloxicam high, Naproxen sodium
- Volunteers
- 390 people
- Sponsor
- Boehringer Ingelheim
Pneumococcal Infections, Pneumonia, Pneumococcal
Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae
This is a randomized, double-blind, placebo-controlled study. Eligible subjects will be randomized in a 1:1 ratio to receive GEN-004 with adjuvant or placebo. Each subject will receive up to 3 doses at 4 week intervals.
- Trial name
- NCT02116998
- Testing
- GEN-004 with Aluminum Hydroxide Adjuvant, Streptococcus pneumoniae inoculation
- Where
- United Kingdom
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Genocea Biosciences, Inc.
Maxillary Sinusitis
AMS VS MOXI Ketek vs Avelox in AMS
Clinical efficacy between telithromycin and moxifloxacin at the post-therapy/test of cure visit, and to assess the safety of telithromycin given once daily for 5 days vs moxifloxacin given once daily for 10 days in the treatment…
- Trial name
- NCT00537563
- Testing
- Telithromycin
- Where
- United States
- Volunteers
- 351 people
- Sponsor
- Sanofi
COVID-19
Clinical Trials to Assess Safety and Efficacy of DWRX2003 Combination With Remdesivir in Moderate to Severe COVID-19 Patients.
Safety and efficacy of DWRX2003 combination with Remdesivir in moderate to severe COVID-19 patients will be confirmed.
- Trial name
- NCT05226533
- Testing
- DWRX2003
- Where
- 3 sites in Indonesia
- Volunteers
- 1 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
COVID-19
An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
The study is Phase II/III and consists of pilot and pivotal stages. The objective of the pilot stage is to conduct a preliminary assessment of the efficacy and safety of Favipiravir, and to select the optimal dosing regimen to…
- Trial name
- NCT04434248
- Testing
- Favipiravir, Standard of Care
- Where
- 22 sites in Russia
- Volunteers
- 330 people
- Sponsor
- Chromis LLC
COVID-19
A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558
A multi-part study of ALG-097558 to evaluate safety, tolerability, pharmacokinetics and drug-drug interaction potential after single and multiple doses in healthy volunteers
- Trial name
- NCT05840952
- Testing
- ALG-097558, Midazolam, Itraconazole
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
Multiple Myeloma
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form…
- Trial name
- NCT02921828
- Where
- 2 sites in United States, Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Covid19
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress
This is a Phase 2 study to assess COVI-MSC in the setting of current standard of care in hospitalized subjects with RT-PCR confirmed SARS-CoV-2 (COVID-19) infection and acute respiratory distress / acute respiratory distress…
- Trial name
- NCT04905836
- Testing
- COVI-MSC
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sorrento Therapeutics, Inc.
Bacterial Pneumonia
Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
This study aims to compare treatment with a fixed-dose combination (FDC) of imipenem/relebactam/cilastatin (IMI/REL) with a FDC of piperacillin/tazobactam (PIP/TAZ) in participants with hospital-acquired or ventilator-associated…
- Trial name
- RESTORE-IMI 2 (NCT02493764)
- Testing
- Imipenem, Relebactam, Cilastatin
- Volunteers
- 537 people
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Respiratory Tract
A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects
This is an open-label, non-randomized, two-period, cross-over, mass balance study that will evaluate the recovery, excretion, and pharmacokinetics of a single intravenous (IV) dose of [14C]-GSK2140944 (Period 1) and a single oral…
- Trial name
- NCT02000765
- Testing
- GSK2140944 for Injection, GSK2140944 Capsule
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pregnancy, Influenza
Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry
The Sanofi Pasteur Fluzone Intradermal Quadrivalent vaccine (Fluzone QIV-ID) Pregnancy Registry will be a prospectively recruited pregnancy surveillance program designed to collect to collect and analyze information on vaccine…
- Trial name
- NCT02554409
- Testing
- Quadrivalent Intradermal Influenza Vaccine (QIV)
- Where
- 5 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19
Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection
Cellular Sciences Inc has submitted over 17 human clinicals (phase I, II, III including animal safety data) to the FDA for the reduction of respiratory inflammation and inflammatory cytokines including IL-6 the cause of the…
- Trial name
- NCT04824365
- Testing
- Sodium Pyruvate, Saline
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cellular Sciences, inc.
COVID-19
A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198
The aim of this phase 2 study is to evaluate the safety and efficacy of single dose IV infusion of BRII-196 and BRII-198 given as combination therapy in patients with severe COVID-19, and mild to moderate COVID-19 and…
- Trial name
- NCT04787211
- Testing
- BRII-196 and BRII-198
- Where
- 6 sites in China
- Volunteers
- 48 people
- Sponsor
- Brii Biosciences Limited
Respiratory Tract Infections, Urinary Tract Infections
Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection
In the proposed study, the investigators plan to evaluate the efficacy and safety of Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for the treatment of respiratory and urinary tract acute bacterial infection.
- Trial name
- PIP-SBT (NCT01760109)
- Testing
- Piperacillin Sodium and Sulbactam Sodium
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Xiangbei Welman Pharmaceutical Co., Ltd
Influenza, Human
A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older
"The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and…
- Trial name
- NCT07121192
- Testing
- Flu mRNA (Formulation A), Flu mRNA (Formulation B), Comparator 1
- Where
- 22 sites in United States
- Volunteers
- 776 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19)
Evaluation of the efficacy and safety of NTX in adult patients (≥18 years and <60 years), with SARS-CoV-2 infection with mild symptoms of COVID-19, compared to a placebo control arm.
- Trial name
- NCT04463264
- Testing
- Nitazoxanide
- Where
- Argentina
- Volunteers
- 135 people
- Sponsor
- Laboratorios Roemmers S.A.I.C.F.
Influenza
Influenza Management With Polyherbal Formulation
The aim of this study is to determine the efficacy of Flu care polyherbal formulation in the management of acute uncomplicated case of Influenza within 48 hours of symptoms onset.
- Trial name
- NCT03365336
- Testing
- polyherbal formulation, Oseltamivir 75mg
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Composite Interceptive Med Science
Influenza, Human
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
The aim of this study is to evaluate the safety, reactogenicity and immunogenicity of the Flu Pandemic messenger RNA (mRNA) vaccine (including dose-finding and dose-confirmation) administered in healthy adults 18 to 85 years of…
- Trial name
- NCT06382311
- Testing
- Flu Pandemic mRNA_Dose level 1, Flu Pandemic mRNA_Dose level 2, Flu Pandemic mRNA_ Dose level 3.
- Where
- 21 sites in United States
- Volunteers
- 991 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Tetanus
Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™
This is a follow-up of Study A3L11 (NCT00404651). Immunogenicity To describe the antibody persistence following a primary series vaccination of either DTaP-IPV-Hep B-PRP~T or Infanrix hexa™.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00654901
- Testing
- DTaP-IPV-Hep B-PRP~T vaccine (Batch 1), DTaP-IPV-Hep B-PRP~T vaccine (Batch 2), DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)
- Where
- 4 sites in Mexico
- Volunteers
- 881 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
SARS-CoV-2 Infection, COVID-19
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals.
- Trial name
- NCT04368728
- Testing
- BNT162b1, BNT162b2, BNT162b2SA
- Where
- 175 sites in United States, Argentina and 4 more
- Volunteers
- 46,969 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.